Daré Bioscience, Inc. (DARE): Price and Financial Metrics


Daré Bioscience, Inc. (DARE): $1.13

0.00 (0.00%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add DARE to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

DARE Stock Price Chart Interactive Chart >

Price chart for DARE

DARE Price/Volume Stats

Current price $1.13 52-week high $2.51
Prev. close $1.13 52-week low $0.92
Day low $1.12 Volume 812,300
Day high $1.17 Avg. volume 1,912,128
50-day MA $1.36 Dividend yield N/A
200-day MA $1.59 Market Cap 95.72M

Daré Bioscience, Inc. (DARE) Company Bio


Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, focuses on developing and marketing products for women's health in the United States. The company intends to develop therapies in the areas of contraception, fertility, and sexual and vaginal health. Its products in advanced clinical development include DARE-BV1, a bioadhesive hydrogel formulated with clindamycin phosphate 2% to treat bacterial vaginosis in a single application that completed Phase 3 clinical trials; Ovaprene, a hormone-free, monthly vaginal contraceptive; and Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder. The company's Phase 1-ready products are DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone replacement therapy; DARE-VVA1, a vaginally delivered formulation of tamoxifen to treat vulvar vaginal atrophy in patients with hormone-receptor positive breast cancer; and DARE-FRT1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth and broader luteal phase support as part of an in vitro fertilization treatment plan. Its products in pre-clinical stage include DARE-LARC1, a combination product designed to provide reversible contraception; ORB-204 and ORB-214 injectable formulations of etonogestrel to provide contraception over 6-month and 12-month periods; and DARE-RH1, a non-hormonal contraception for men and women. The company is based in San Diego, California.


DARE Latest News Stream


Event/Time News Detail
Loading, please wait...

DARE Latest Social Stream


Loading social stream, please wait...

View Full DARE Social Stream

Latest DARE News From Around the Web

Below are the latest news stories about Dare Bioscience Inc that investors may wish to consider to help them evaluate DARE as an investment opportunity.

Daré Bioscience (DARE) Investor Presentation - Slideshow

The following slide deck was published by Daré Bioscience, Inc. in conjunction with this event....

SA Transcripts on Seeking Alpha | February 17, 2022

Daré Bioscience to Participate in Upcoming Conferences

SAN DIEGO, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, its President and Chief Executive Officer, will participate in the following upcoming conferences: 2022 BIO CEO & Investor ConferenceFebruary 14-17, 2022, New York Marriott Marquis and VirtualIn-person Presentation Monday, February 14, 2022 at 2:15 p.m. EST SVB Leerink Virtual 11th Annual Global Healthcare ConferenceFebruary 14-1

Yahoo | February 7, 2022

Analysts Have Conflicting Sentiments on These Healthcare Companies: Zogenix (ZGNX) and Daré Bioscience (DARE)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Zogenix (ZGNX – Research Report) and Daré Bioscience (DARE – Research Report). Zogenix (ZGNX) In a report released today, Serge Belanger from Needham downgraded Zogenix to Hold. The company's shares closed last Wednesday at $26.19. According to TipRanks.

Brian Anderson on TipRanks | January 19, 2022

Dawson James Remains a Buy on Daré Bioscience (DARE)

Dawson James analyst Jason Kolbert maintained a Buy rating on Daré Bioscience (DARE – Research Report) on November 23 and set a price target of $3.00. The company's shares closed last Thursday at $1.84. According to TipRanks.com, Kolbert is a 4-star analyst with an average return of 5.0% and a 41.9% success rate. Kolbert covers the Healthcare sector, focusing on stocks such as Brainstorm Cell Therapeutics, Citius Pharmaceuticals, and Sorrento Therapeutics. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Daré Bioscience with a $3.67 average price target, a 102.8% upside from current levels.

Brian Anderson on TipRanks | January 7, 2022

Dawson James Sticks to Their Buy Rating for Daré Bioscience (DARE)

Dawson James analyst Jason Kolbert maintained a Buy rating on Daré Bioscience (DARE – Research Report) on December 8 and set a price target of $3.00. The company's shares closed last Thursday at $1.84. According to TipRanks.com, Kolbert is a 4-star analyst with an average return of 5.0% and a 41.9% success rate. Kolbert covers the Healthcare sector, focusing on stocks such as Brainstorm Cell Therapeutics, Citius Pharmaceuticals, and Sorrento Therapeutics. Daré Bioscience has an analyst consensus of Strong Buy, with a price target consensus of $3.67, implying a 102.8% upside from current levels. In a report issued on December 8, H.C.

Christine Brown on TipRanks | January 7, 2022

Read More 'DARE' Stories Here

DARE Price Returns

1-mo -13.74%
3-mo -27.10%
6-mo -32.34%
1-year -17.52%
3-year 26.82%
5-year -73.10%
YTD -43.50%
2021 49.25%
2020 63.41%
2019 15.49%
2018 -67.13%
2017 -69.58%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7857 seconds.